MX2021008672A - Competidores de cd31 y usos de los mismos. - Google Patents

Competidores de cd31 y usos de los mismos.

Info

Publication number
MX2021008672A
MX2021008672A MX2021008672A MX2021008672A MX2021008672A MX 2021008672 A MX2021008672 A MX 2021008672A MX 2021008672 A MX2021008672 A MX 2021008672A MX 2021008672 A MX2021008672 A MX 2021008672A MX 2021008672 A MX2021008672 A MX 2021008672A
Authority
MX
Mexico
Prior art keywords
diseases
present
cds
binding
relates
Prior art date
Application number
MX2021008672A
Other languages
English (en)
Inventor
Laurence Bressac
Serge Guerreiro
Damien Toulorge
Original Assignee
Encefa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encefa filed Critical Encefa
Publication of MX2021008672A publication Critical patent/MX2021008672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Abstract

La presente invención se refiere a anticuerpos anti-CD38 humanos aislados o fragmentos de unión a antígeno de los mismos; a ácidos nucleicos y vectores de expresión que codifican los mismos. La presente invención se refiere además a compuestos que compiten específicamente con CD31 para la unión de CD38, para su uso en la prevención y/o el tratamiento de una enfermedad seleccionada de enfermedades neurodegenerativas, enfermedades neuroinflamatorias, enfermedades inflamatorias, enfermedades autoinmunes, enfermedades metabólicas, enfermedades oculares, enfermedades relacionadas con la edad, cáncer y metástasis en un sujeto que lo necesita.
MX2021008672A 2019-01-23 2020-01-23 Competidores de cd31 y usos de los mismos. MX2021008672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305086 2019-01-23
PCT/EP2020/051667 WO2020152290A1 (en) 2019-01-23 2020-01-23 Cd31 competitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2021008672A true MX2021008672A (es) 2021-11-03

Family

ID=65409014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008672A MX2021008672A (es) 2019-01-23 2020-01-23 Competidores de cd31 y usos de los mismos.

Country Status (13)

Country Link
US (1) US20220089765A1 (es)
EP (1) EP3914616A1 (es)
JP (1) JP2022523047A (es)
KR (1) KR20210119448A (es)
CN (1) CN113614107A (es)
AU (1) AU2020211728A1 (es)
BR (1) BR112021014574A2 (es)
CA (1) CA3127520A1 (es)
IL (1) IL284962A (es)
MX (1) MX2021008672A (es)
SG (1) SG11202107941TA (es)
WO (1) WO2020152290A1 (es)
ZA (1) ZA202105154B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8088896B2 (en) * 2005-10-12 2012-01-03 Morphosys Ag Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
KR20080068089A (ko) 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
DK2336329T3 (da) 2007-06-01 2013-01-07 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
CN110317272A (zh) 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
AU2016283343B2 (en) 2015-06-24 2022-05-19 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody permeating blood-brain barrier
JP7237950B2 (ja) * 2017-06-08 2023-03-13 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体

Also Published As

Publication number Publication date
EP3914616A1 (en) 2021-12-01
IL284962A (en) 2021-09-30
BR112021014574A2 (pt) 2021-10-05
KR20210119448A (ko) 2021-10-05
SG11202107941TA (en) 2021-08-30
AU2020211728A1 (en) 2021-08-12
WO2020152290A1 (en) 2020-07-30
CN113614107A (zh) 2021-11-05
CA3127520A1 (en) 2020-07-30
ZA202105154B (en) 2023-01-25
JP2022523047A (ja) 2022-04-21
US20220089765A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2017001531A (es) Anticuerpos anti-trem2 y metodos de uso de los mismos.
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
MX2021001074A (es) Ratones de cadena ligera universal humanizados.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
MX2020003087A (es) Anticuerpos anti-cd3epsilon novedosos.
PH12021550244A1 (en) Anti-btla antibody
PH12020550825A1 (en) Anti-c5 antibody combinations and uses thereof
PH12021550054A1 (en) Variants of cd38 antibody and uses thereof
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
MX2020012539A (es) Anticuerpos especificos para cd3 y sus usos.
SA519401032B1 (ar) (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه
IN2014MN02231A (es)
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
MX2021008672A (es) Competidores de cd31 y usos de los mismos.
WO2015191590A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
MX2019009137A (es) Inhibicion de agregacion plaquetaria usando anticuerpos gpvi antihumanos.
MX2022006145A (es) Anticuerpos trem2 y usos de estos.
JOP20210100A1 (ar) جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20
EA202191821A1 (ru) Группы, связывающие клаудин 18.2, и их использование